Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

	Hepatology
	The latest hepatology news from News Medical

	Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

	Kyoto University unveils noninvasive assessment for diabetes In type 1 diabetes, the immune system starts to destroy insulin-producing beta cells in the pancreas. Progressive loss of these cells destabilizes the body's glucose levels and drives the course of the disease, so preserving or restoring beta cell mass is a central treatment goal.

			Experimental therapy eliminates pancreatic precancerous cells in mice study A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.

			Low testosterone and high fructose intake can worsen fatty liver disease Low testosterone in itself can cause a variety of health problems, but the addition of a poor diet can exacerbate certain conditions. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one example that approximately 40% of adult men worldwide currently suffer from and has become a global problem.

			New insight into origins of rare liver tumors in children Liver cancer in children is rare, but when it occurs the two main types are hepatoblastoma (HB) and hepatocellular carcinoma (HCC).

	Scientists uncover unexpected cancer target on tumor cell surfaces For five decades, scientists have known about a notorious cancer-causing enzyme called SRC. But they always assumed it only appeared on the inside of cells, where it sent signals that fueled tumor growth and stayed hidden from the immune system.

	Dual-positive hybrid cells linked to shorter survival in advanced breast cancer An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

	Expert consensus validates UDFF for noninvasive fatty liver assessment As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2026